What’s new in primary ITP? Key updates from ASH 2024

touchPODCAST

Player FM - Internet Radio Done Right

اضافه شده در three سال پیش

محتوای ارائه شده توسط touchpodcast. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط touchpodcast یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Tickets to Travel

1
Ep 36 - Free Tickets, Full Venues: Loudie's Lance Dashoff Has the Hookup! 48:45

23 روز پیش48:45

پخش در آینده

لیست ها

پسندیدن

دوست داشته شد

48:45

FREE TICKETS?! Yes, really. In this episode of Tickets to Travel: The Business of Travel Experiences , we’re joined by the ultimate guest list insider, Lance Dashoff, founder of Loudie — the app that’s quietly revolutionizing how fans score free concert, comedy, and festival tickets across the U.S. From his early days at WME curating VIP access, to launching a platform that fills empty seats and fuels unforgettable nights out, Lance spills the tea on: Why 30–40% of tickets go unsold How promoters are secretly using free ticketing to boost bar sales and fan buzz The economics behind live events and why not all sold-out shows are actually sold out How Loudie helps fans and venues win — without the scammy vibes Why travel pros and concierges should start recommending this app yesterday Whether you’re in LA, NYC, or stuck in traffic on the way to Philly — this is the episode you can’t afford to miss (literally). Download Loudie, follow us @tix2travelpod on TikTok, IG, and YouTube, and grab your next night out before someone else does. Because every ticket is a ticket to travel — and sometimes the best ones are free. www.tttpod.com…

حدود یک سال پیش 40:35

MP3•خانه قسمت

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.

The experts

Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website:
https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

102 قسمت

#Science #TouchPODCAST

What’s new in primary ITP? Key updates from ASH 2024

touchPODCAST

published حدود یک سال پیش

اشتراک گذاری

MP3•خانه قسمت

touchPANEL DISCUSSION for touchONCOLOGY

The experts

Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website:
https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

102 قسمت

#Science #TouchPODCAST

همه قسمت ها

1
RET-positive NSCLC: Translating insights into targeted approaches 14:36

22 روز پیش14:36

14:36

touchFOCUS for touchONCOLOGY In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC. The expert: Dr Christine Bestvina - University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc . This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com…

1
RET-positive NSCLC: Translating insights into targeted approaches 14:36

22 روز پیش14:36

14:36

touchFOCUS for touchRESPIRATORY In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC. The expert: Dr Christine Bestvina - University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc . This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchrespiratory.com…

1
Advances in dry eye disease: From diagnosis to new treatment targets 37:43

29 روز پیش37:43

37:43

touchEXPERT FOCUS touchOPHTHALMOLOGY Listen to Dr Laura Periman share expert insights on dry eye disease. In this episode, she explores the pathophysiological mechanisms behind the condition, highlights key diagnostic tools, reviews current treatment options—including exciting advances in neuromodulation therapies—and discusses emerging targeted approaches shaping clinical management today. The expert Dr Laura Periman, Periman Eye Institute, Seattle, WA, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from A lcon Vision, LLC. The activity is jointly provided by USF Health and touchIME. For further information, visit our website: https://touchophthalmologyime.org/advances-in-dry-eye-disease/…

1
Recent advances in the care of patients with geographic atrophy: Bringing new and emerging therapies into focus 35:33

۴ weeks پیش35:33

35:33

touchIN CONVERSATION for touchOPHTHALMOLOGY Listen to two experts in geographic atrophy (GA) discuss recent advances in the care of patients. They explore the importance of early identification of GA and how this can be achieved, examine the potential impact of new and emerging therapies for GA, and highlight key practical considerations for monitoring treatment outcomes and evaluating effectiveness of therapy in clinical practice. The experts Prof. Giuseppe Querques, IRCCS Hospital San Raffaele, Milan, Italy Dr Arshad M. Khanani, Sierra Eye Associates, Reno, NV, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Astellas Pharma Inc. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: https://touchophthalmologyime.org/…

1
The potential of BTKi therapies in delaying MS progression 13:32

۵ weeks پیش13:32

13:32

touchEXPERT FOCUS for touchNEUROLOGY Join Prof. Montalban as he shares expert insights into the pathophysiology of progressive MS and the rationale for targeting BTK inhibitors. He reviews emerging clinical data supporting the use of BTK inhibitors and discusses how they may fit into the evolving treatment landscape. In this context, Prof. Montalban also considers current guideline-recommended therapies for progressive MS and highlights key areas of remaining unmet treatment need. The expert Prof. Xavier Montalban, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Vall d'Hebron University Hospital, Barcelona, Spain This touchPODCAST is for HCPs outside of the UK only. This activity is provided by an independent medical education grant from Sanofi. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchneurology.com/…

1
Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors 30:27

۵ weeks پیش30:27

30:27

touchPANEL DISCUSSION for touchNEUROLOGY Listen to two expert neurologists and a neurology nurse as they explore the role of neonatal Fc receptor (FcRn) inhibitors in improving the burden of disease in patients with generalized myasthenia gravis. The faculty will consider how the burden of disease and treatment in patients with generalized myasthenia gravis can be used to inform treatment decisions, the latest clinical data for FcRn inhibitors and the best practice strategies for using FcRn inhibitors in clinical practice. The experts Prof. Michael Nicolle – Western University and London Health Sciences Centre, London, ON, Canada Dr Karissa Gable – Duke University, Durham, NC, USA Ms Missy Pittman – Duke University, Durham, NC, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Argenx and UCB, Inc. The activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurologyime.org/reducing-burden-of-disease-in-gmg-exploring-the-role-of-fcrn-inhibitors/…

1
MDT perspectives on why and how to implement continuous glucose monitoring in T2D 13:26

۵ weeks پیش13:26

13:26

Listen to key experts from a multidisciplinary team review and discuss why and how to implement continuous glucose monitoring in T2D. The multidisciplinary team Endocrinologist: Prof Tina Vilsbøll Primary Care Physician: Dr Gihane Zarifa Nurse specialist: Ms. Lori Berard Patient advocate: Mr. Ostap Soroka This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/…

1
MDT perspectives on evolving options for insulin therapy 10:05

۵ weeks پیش10:05

10:05

Listen to key experts from a multidisciplinary team review and discuss evolving options for insulin therapy. The multidisciplinary team Endocrinologist: Prof Tina Vilsbøll Primary Care Physician: Dr Gihane Zarifa This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/…

1
MDT perspectives on understanding clinical inertia in T2D 12:14

۵ weeks پیش12:14

12:14

Listen to key experts from a multidisciplinary team review and discuss clinical inertia in T2D. The multidisciplinary team Endocrinologist: Prof Tina Vilsbøll Primary Care Physician: Dr Gihane Zarifa Patient advocate: Mr. Ostap Soroka This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/…

1
Navigating the clinical impact of TROP2-targeting in NSCLC 55:41

۶ weeks پیش55:41

55:41

touchSYMPOSIUM for touchONCOLOGY Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France. Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC. Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation Session 2: Prof. Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/…

1
Navigating the clinical impact of TROP2-targeting in NSCLC 55:41

۶ weeks پیش55:41

55:41

touchSYMPOSIUM for touchRESPIRATORY Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France. Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC. Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation Session 2: Prof. Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/…

1
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY 33:43

۸ weeks پیش33:43

33:43

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of world-leading experts in lysosomal storage disorders explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes. The experts Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA Dr Christina Lampe, University of Giessen, Giessen, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Chiesi USA, Inc. The activity is jointly provided by USF Health and touchIME. For further information visit: touchneurologyime.org/…

1
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY 33:45

۸ weeks پیش33:45

33:45

touchPANEL DISCUSSION for touchENDOCRINOLOGY Listen to a panel of world-leading experts in lysosomal storage disorders explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes. The experts Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA Dr Christina Lampe, University of Giessen, Giessen, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Chiesi USA, Inc. The activity is jointly provided by USF Health and touchIME. For further information visit: touchendocrinologyime.org/…

1
The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy 38:58

۸ weeks پیش38:58

38:58

touchIN CONVERSATION for touchONCOLOGY Listen to two expert gynaecologic oncology specialists discuss the evolving role of immunotherapy in the treatment of advanced/recurrent endometrial cancer. They explore how immune checkpoint inhibitors are reshaping standards of care across lines of therapy, highlight key practical considerations for optimizing patient selection and management, and examine emerging data that may influence future treatment paradigms. The experts Dr Alexandra Leary, Gustave Roussy Cancer Center, Villejuif, France Dr Juan Francisco Grau, Gustave Roussy Cancer Center, Villejuif, France This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/…

1
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia 35:35

۹ weeks پیش35:35

35:35

touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three experts as they explore the burden of myelofibrosis and anaemia and/or thrombocytopenia, discuss targeted treatment strategies and how to maximize benefits for patients. The experts Prof. Haifa Kathrin Al-Ali – University Hospital of Halle, Halle (Saale), Germany Prof. Jean-Jacques Kiladjian – Université Paris Cité and Saint-Louis Hospital, Paris, France Prof. Alessandro Vannucchi – University of Florence, Florence, Italy This touchPODCAST is for HCPs outside of the UK and USA only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/…

touchPODCAST

1
Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer 11:54

۹ weeks پیش11:54

11:54

Listen to key experts from a multidisciplinary team consider the strategies to avoid, mitigate, identify and effectively manage side effects associated with ADCs in patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA Clinical oncology pharmacy specialist: Dr Scott Edwards, Dr. H. Bliss Murphy Cancer Center, St. John’s, Newfoundland, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer 13:03

۹ weeks پیش13:03

13:03

Listen to key experts from a multidisciplinary team discuss effective strategies for communicating the potential side effects associated with ADC treatment to patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA Patient advocate: Mrs Lesley Turner, Independent Cancer Patients’ Voice, UK This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer 11:59

۹ weeks پیش11:59

11:59

Listen to key experts from a multidisciplinary team review and discuss the safety profiles of current and emerging ADCs in patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease 19:12

10 weeks پیش19:12

19:12

touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to retina specialist Prof. Peter Kaiser answer a series of questions on the current clinical landscape for neovascular age-related macular degeneration and diabetic macular oedema, share his perspective on how newly available treatments are influencing the existing standard of care and provide guidance on how new therapies can be effectively integrated into clinical practice. The expert Prof. Peter Kaiser, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from Bayer Consumer Care AG. The activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchophthalmologyime.org/adopting-emerging-therapies-for-retinal-diseases…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

11 weeks پیش1:06:26

1:06:26

touchCONGRESS for touchCARDIO Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, German This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:27

11 weeks پیش1:06:27

1:06:27

touchCONGRESS for touchENDOCRINOLOGY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

11 weeks پیش1:06:26

1:06:26

touchCONGRESS for touchNEUROLOGY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease Using data to guide clinical practice 1:06:27

11 weeks پیش1:06:27

1:06:27

touchCONGRESS for touchRESPIRATORY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
MDT perspectives on the importance of patient engagement in PARPi use - Video 3 13:21

13 weeks پیش13:21

13:21

touchMDT for touchONCOLOGY Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors. The multidisciplinary team and patient advocate: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Patient Advocate – Mr Tony Collier Tackle Prostate Cancer, London, UK This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2 13:45

13 weeks پیش13:45

13:45

touchMDT for touchONCOLOGY Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen. The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Pathologist – Prof. Albrecht Stenzinger University of Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1 13:44

13 weeks پیش13:44

13:44

touchMDT for touchONCOLOGY MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC). The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY 32:02

14 weeks پیش32:02

32:02

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchENDOCRINOLOGY.com…

touchPODCAST

1
The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO 32:01

14 weeks پیش32:01

32:01

touchEXPERT OPINIONS for touchCARDIO Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchCARDIO.com…

touchPODCAST

1
From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer 36:50

15 weeks پیش36:50

36:50

touchEXPERT OPINIONS for touchONCOLOGY Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations. The experts Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain This touchPODCAST is for healthcare professionals outside of the UK and the USA. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

15 weeks پیش36:26

36:26

touchIN CONVERSATION for touchINFECTIOUS DISEASES Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC ® accredited provider. For further information visit our website: https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/…

touchPODCAST

1
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

15 weeks پیش36:26

36:26

touchIN CONVERSATION for touchONCOLOGY Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC ® accredited provider. For further information visit our website: https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/…

touchPODCAST

1
Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

15 weeks پیش16:31

16:31

touchFOCUS for touchHAEMATOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchHAEMATOLOGY.com…

touchPODCAST

1
Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

15 weeks پیش16:31

16:31

touchFOCUS for touchONCOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com…

touchPODCAST

1
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

17 weeks پیش55:57

55:57

touchCONGRESS for ONCOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…

touchPODCAST

1
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

17 weeks پیش55:57

55:57

touchCONGRESS for touchHAEMATOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…

touchPODCAST

1
RAS mutations and personalized cancer care: Targeting the future 31:02

18 weeks پیش31:02

31:02

touchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines . This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/…

touchPODCAST

1
What’s new in primary ITP? Key updates from ASH 2024 40:35

18 weeks پیش40:35

40:35

touchPANEL DISCUSSION for touchONCOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…

touchPODCAST

1
What’s new in primary ITP? Key updates from ASH 2024 40:35

18 weeks پیش40:35

40:35

touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…

touchPODCAST

1
Focused insights: Data implications of ADCs in NSCLC treatment 21:54

19 weeks پیش21:54

21:54

touchFOCUS for touchRESPIRATORY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchrespiratory.org/ADCs-in-NSCLC…

touchPODCAST

1
Focused insights: Data implications of ADCs in NSCLC treatment 21:54

19 weeks پیش21:54

21:54

touchFOCUS for touchONCOLOGY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/ADCs-in-NSCLC…

touchPODCAST

1
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY 1:20:58

19 weeks پیش1:20:58

1:20:58

touchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA. Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic This touchPODCAST is for HCPs in the USA. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncologyime.org…

touchPODCAST

1
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY 1:20:58

19 weeks پیش1:20:58

1:20:58

touchPODCAST

1
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37

21 weeks پیش37:37

37:37

touchEXPERT FOCUS for touchONCOLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Springworks Therapeutics, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/expert-focus-management-of-nf1/…

touchPODCAST

1
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38

21 weeks پیش37:38

37:38

touchEXPERT FOCUS for touchNEUROLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Springworks Therapeutics, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurologyime.org/expert-focus-management-of-nf1/…

touchPODCAST

1
Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15

24 weeks پیش38:15

38:15

touchEXPERT OPINIONS for touchONCOLOGY Listen to an oncologist, urologist and oncology nurse highlight the key data for immunotherapy in the perioperative setting for muscle-invasive bladder cancer, practical considerations for its use in clinical practice, and how possible side effects can be monitored for and managed. They also consider the role of the multidisciplinary team in implementing this treatment modality. The experts Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands Prof. Thomas Powles, Barts Cancer Centre, London, UK Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.